Haemophilus influenzae is an important pathogen in man. Encapsulated H. influenzae type b is a leading cause of bacteremia, pneumonia and meningitis in infancy in the United States. Unencapsulated or nontypable H. influenzae is an important cause of sepsis in the newborn and in certain immunocompromised patients and of infection in the middle ear and in the respiratory tract in adults and children. The goal of this proposed study is to define the molecular bases of the clearance of H. influenzae from the bloodstream. Previous studies indicate that this process of clearance depends upon receptor-mediated phagocytosis of these pathogens by fixed macrophages. Therefore, in the proposed work the interaction of H. influenzae with the macrophage will be examined. Since the understanding of how microbes interact with macrophages is largely based on work done with intracellular pathogens, the proposed study will concentrate on examining the role of specific receptors and ligands previously defined to mediate binding and ingestion of these organisms. This study, however, will begin to define how these mechanisms are used in defending the host from extracellular bacterial pathogens. The approach will be to determine (1) the specificity and physiology of the macrophage receptors which mediate direct binding of H. influenzae, (2) the bacterial surface components which act as ligands to these receptors, (3) the effects of antibody and serum complement as ligands for the interaction of H. influenzae with macrophages and (4) the potential for macrophage activation to modify this bacteria-macrophage interaction. This study will be conducted using in vitro culture systems for both murine and human macrohages along with in vivo study of H. influenzae bloodstream clearance in a murine model. This work is expected to define mechanisms critical in defending the immune and nonimmune host from infection due to H. influenzae. In doing so, it is expected that advances in designing effective prophylactic and therapeutic regimens aimed at these infections will be realized.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI030063-05
Application #
2065416
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1990-09-01
Project End
1996-07-31
Budget Start
1994-08-01
Budget End
1996-07-31
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Frey, Sharon E; Bernstein, David I; Brady, Rebecca C et al. (2015) Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine 33:163-73
Kotloff, Karen L; Halasa, Natasha B; Harrison, Christopher J et al. (2014) Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. Pediatr Infect Dis J 33:865-71
Gowen, Brian B; Jung, Kie-Hoon; Sefing, Eric J et al. (2014) Activity of a phenolic dibenzylsulfide against New World arenavirus infections. Antivir Chem Chemother 23:151-9
Smee, Donald F; Tarbet, E Bart; Furuta, Yousuke et al. (2013) Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 8:1085-1094
Sefing, Eric J; Wong, Min-Hui; Larson, Deanna P et al. (2013) Vascular leak ensues a vigorous proinflammatory cytokine response to Tacaribe arenavirus infection in AG129 mice. Virol J 10:221
Smee, Donald F; Julander, Justin G; Tarbet, E Bart et al. (2012) Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. Antiviral Res 96:13-20
Smee, Donald F; Hurst, Brett L; Day, Craig W (2012) D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 22:263-72
Esteban, David; Parker, Scott; Schriewer, Jill et al. (2012) Mousepox, a small animal model of smallpox. Methods Mol Biol 890:177-98
Murray, James L; McDonald, Natalie J; Sheng, Jinsong et al. (2012) Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother 22:205-15

Showing the most recent 10 out of 54 publications